• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders
 

Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

on

  • 212 views

 

Statistics

Views

Total Views
212
Views on SlideShare
212
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Document Transcript

    • Global Markets for Treatments for Syndromes of ProgressiveAtaxia and Weakness DisordersReport Details:Published:October 2012No. of Pages: 170Price: Single User License – US$4850•The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.•Treatments for progressive weakness syndromes should total nearly $14.6 billion in 2012 and $22.8 billion in 2017, a CAGR of 9.4%.•Progressive ataxia treatments are expected to have a value of $356.4 million in 2012 and $620.7 million in 2017, a CAGR of 11.7%.STUDY OBJECTIVESBCC’s goal in conducting this study is to provide an overview of the current and futurecharacteristics of the global market for treatments of neurodegenerative (i.e., progressive ataxiaand weakness) disorders. The key objective is to present a comprehensive analysis and thefuture direction of treatments for these disorders as the market efforts toward drug and therapydevelopment evolve.This report explores present and future strategies within the progressive ataxia and weaknessdisorders market, which includes treatments and therapies for dysfunctions, including progressiveataxia and progressive weakness disorder syndromes. The market’s improvisation, setbacks andneeds are also discussed. The comparisons, usage, advantages and disadvantages of differenttypes of technologies, including small-molecule and monoclonal antibodies, are also presented.A detailed analysis of the industry structure has been conducted. Revenues are broken down bythe neurodegenerative dysfunction. Sales figures are estimated for the five-year period from 2012through 2017.The report discusses applications for neurodegenerative disorder treatment and therapytechnologies, with emphasis on small-molecule and monoclonal antibodies technology. The reportalso covers significant patents and their allotments in each category.REASONS FOR DOING THIS STUDYExtensive research in the field of progressive ataxia and weakness disorders as well ascollaborations with research institutes have highlighted the importance of understanding the natureof these disorders. New technology development is providing modifying therapies for the late
    • stages of these disorders. Collaborations among research institutes and pharmaceuticalcompanies are becoming more common, as state-of-the-art technology is being explored todevelop more-efficient products and therapies.R&D spending, increasing competition, patent expiries and new technologies are shifting themarket in a new direction. The market’s overall revenue has increased from 2009 to 2011, and itcontinues to show growth, as new advancements, product launches and collaborations will havepositive influences for the foreseeable future. This study looks at most of the systems affected bythese factors.Acquisition strategies and company collaborations are also covered in this report. This studydiscusses the strength and weaknesses of each technology in light of the new developments,growing competition and changing customer needs.CONTRIBUTIONS OF THE STUDY AND FOR WHOMThis study contributes to the areas of market growth in Friedreich’s ataxia, Gerstmann-Straussler-Scheinker disease, Machado-Joseph disease, amyotrophic lateral sclerosis, progressive bulbarpalsy, hereditary spastic paraplegia, hereditary neuropathies and multiple sclerosis.Pharmaceutical biotechnical companies, research institutes and physicians will find this study ofinterest.SCOPE OF THE STUDYThe scope of this study encompasses the neurodegenerative (i.e., progressive ataxia andweakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes eachmarket and its applications, the regulatory environments, and the technologies involved, as well asmarket projections and market shares. Technological issues include the latest trends anddevelopments. The emerging market for enzyme inhibitors includes such countries as India,China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand.METHODOLOGYBoth primary and secondary research methodologies were used in preparing this study. BCCconducted a comprehensive literature search, which included technical newsletters and journals,among other sources. Data were collected through interviews and correspondence with technicalexperts at companies that manufacture enzyme inhibitors. Projections were based on estimatesthat were calculated such using information as the current number of end users, potential endusers, mergers and acquisitions, and market trends.INFORMATION SOURCESMany companies within the industry were surveyed to obtain data for this study. These includedmanufacturers and end users of enzyme inhibitors in therapeutic categories and various disease-sector industries. Data were gathered from various industry sources. BCC spoke with officialswithin the industry and also reviewed newsletters, company literature and product literature, aswell as a host of technical articles, journals, indices and abstracts. Exhaustive investigations ofdatabases by key terminology were completed. In addition, data were compiled from currentfinancial, trade and government sources.Get your copy of this report @http://www.reportsnreports.com/reports/197565-global-markets-for-treatments-for-syndromes-of-progressive-ataxia-and-weakness-disorders.html
    • Major points covered in Table of Contents of this report includeTable Of ContentsChapter- 1: Introduction - Complimentary 3Study ObjectivesReasons For Doing This StudyContributions Of The Study And For WhomScope Of The StudyMethodologyInformation SourcesAbout The AuthorRelated Bcc Research ReportsBcc On-Line ServicesDisclaimerChapter- 2: Executive Summary 2Table Summary : Global Market For Progressive Ataxia And Weakness Disorders, Through 2017Figure Summary : Global Market For Progressive Ataxia And Weakness Disorders, 2010-2017Chapter- 3: Overview 6DefinitionsClassificationProgressive Ataxia And Weakness DisordersDiagnostic Tests For Progressive Ataxia And Weakness DisordersChapter- 4: Regulatory Aspects 4Drug Approvals For Progressive Ataxia And Weakness DisordersRegulatory Developments Of Products Used To Treat Progressive Ataxia And WeaknessDisordersChapter- 5: New Developments 8Table 6 : New Developments For The Treatment Of Progressive Ataxia And Weakness Disorders,2012Table 7 : New Developments For The Treatment Of Progressive Ataxia And Weakness Disorders,2011Table 8 : New Developments In The Treatment Of Progressive Ataxia And Weakness Disorders,2010Chapter- 6: Global Markets 13Markets By DysfunctionMarkets By DisordersMarket By RegionsMarkets By TechnologyChapter- 7: Progressive Ataxia Syndrome Market 27Market By Disease TypeMarket By RegionMarket By TechnologyIndustry Structure
    • Chapter- 8: Progressive Weakness Syndrome Markets 48Market By Disease TypeMarkets By RegionMarket By TechnologyIndustry StructureChapter- 9: Patent Analysis 13Patents By YearPatents By Disease CategoryPatents By Disease TypePatents By CountryPatents By CompanyPatents By AssigneeChapter- 10: Current Situation 6Market TrendsAdditional Drivers For Progressive Ataxia And Weakness Disorders Drug MarketFactors Governing The MarketCollaborations, Mergers And AcquisitionsChapter- 11: Company Profiles 37Abbott LaboratoriesAcorda Therapeutics Inc.Actavis ElizabethAllon Therapeutics IncAmerican Regent Inc.Apotex Inc.Apotheca, Inc.App PharmaceuticalsAstellas Pharma Inc.Astrazeneca GmbhAurobindo Pharma LtdBaxter International Inc.Biogen IdecBoehringer Ingelheim Ltd.Bristol-Myers SquibbBryant Ranch PrepackCadila Healthcare Ltd.Caraco Pharmaceutical LaboratoriesCardinal HealthCognition Pharmaceuticals LlcCsl BehringDr. Reddys Laboratories LimitedEisai Co. LtdElan Pharma International Limited
    • Eli Lilly And CompanyEmd Millipore HeadquartersEndo Pharmaceuticals IncGlaxosmithkline Plc.Glenmark Generics LimitedH. Lundbeck A/SHameln Pharmaceuticals LtdHospira Inc.Intellect Neurosciences Inc.Jazz Pharmaceuticals Plc.Lexicon Pharmaceuticals Inc.Major PharmaceuticalsMerck SeronoMerck Sharp & Dohme LimitedMerz Pharma Gmbh & Co KgaaMomenta PharmaceuticalsMylan PharmaceuticalsNeuren Pharmaceuticals Ltd.Neurosearch A/SNoscira, S.A.Novartis AgOrchid Chemicals & Pharmaceuticals Ltd.Ortho-Mcneil Janssen Pharmaceuticals Inc.Par PharmaceuticalsPerrigo CompanyPfizer Inc.PharnextPhysicians Total Care, Inc.Pliva Hrvatska D.O.O.PrometheusRanbaxy Laboratories LimitedRoche Holding LtdRoxane Laboratories Inc.Sandoz International GmbhSanofiSanthera PharmaceuticalsShionogi & Co.Sun PharmaTaj Pharmaceuticals LimitedTakeda Pharmaceutical Company LimitedTercica, IncTeva Pharmaceutical Industries Ltd
    • Torrent PharmaUcb S.A.Udl LaboratoriesUpsher-Smith LaboratoriesWatson Pharmaceuticals Inc.West-Ward PharmaceuticalChapter- 12: Appendix I: Abbreviations 3List Of TablesSummary Table : Global Market For Progressive Ataxia And Weakness Disorders, Through 2017Table 1 : Classification By Primary DysfunctionTable 2 : Abbreviated Approvals And New Drug Approvals For Progressive Ataxia And WeaknessDisorders, 2012Table 3 : New Drug Applications For The Progressive Ataxia And Weakness DisordersTable 4 : Safety Alerts, 2010-March 2012Table 5 : Recalls For Drugs Used To Treat Progressive Ataxia And Weakness Disorders,2010–March 2012Table 6 : New Developments For The Treatment Of Progressive Ataxia And Weakness Disorders,2012Table 7 : New Developments For The Treatment Of Progressive Ataxia And Weakness Disorders,2011Table 8 : New Developments In The Treatment Of Progressive Ataxia And Weakness Disorders,2010Table 9 : Global Revenues Of Drug Products For The Treatment Of NeurodegenerativeDysfunctions, Through 2017Table 10 : Market Share Of Drugs Used For The Treatment Of Neurodegenerative Disorders ByDysfunctions, 2011Table 11 : Global Sales Of Drug Products For The Treatment Of Progressive Ataxia AndWeakness Disorders, Through 2017Table 12 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia AndWeakness Disorders, 2011Table 13 : Market For Drug Products For The Treatment Of Progressive Ataxia And WeaknessDisorders By Region, Through 2017Table 14 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia AndWeakness Disorders By Region, 2011Table 15 : Global Sales Of Drug Products For The Treatment Of Progressive Ataxia AndWeakness Disorders By Technology, Through 2017Table 16 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia AndWeakness Disorders By Technology, 2011Table 17 : Sales Of Drug Products For The Treatment Of Progressive Ataxia By Disease Type,Through 2017Table 18 : Progressive Ataxia Drug Market By Disease Type, 2011Table 19 : Progressive Ataxia Drug Market By Region, Through 2017
    • Table 20 : Progressive Ataxia Drug Market By Region, 2011Table 21 : Friedreich’s Ataxia Drug Market By Region, Through 2017Table 22 : Gertsmann-Straussler-Scheinker Disease Drug Market By Region, Through 2017Table 23 : Machado-Joseph Disease Drug Market By Region, Through 2017Table 24 : Progressive Ataxia Drug Market By Technology, Through 2017Table 25 : Progressive Ataxia Drugs Share By Technology, 2011Table 26 : Leading Manufacturers And Suppliers Of Friedreich’s Ataxia Drugs And TherapiesTable 27 : Market Shares For Manufacturers And Distributors Of Friedreich’s Ataxia Drugs, 2011Table 28 : Leading Manufacturers And Suppliers Of Gerstmann-Straussler-Scheinker DiseaseDrugs And TherapiesTable 29 : Market Shares Of Manufacturers And Distributors Of Gertsmann-Straussler-ScheinkerDisease Drugs, 2011Table 30 : Leading Manufacturers And Suppliers Of Machado-Joseph Disease Drugs AndTherapiesTable 31 : Market Shares Of Manufacturers And Distributors Of Machado-Joseph Disease Drugs,2011Table 32 : Progressive Weakness Syndrome Drug Market By Disease Type, Through 2017Table 33 : Progressive Weakness Drug Market By Disease Type, 2011Table 34 : Progressive Weakness Syndrome Drug Market By Region, Through 2017Table 35 : Progressive Weakness Drug Market By Region, 2011Table 36 : Amyotrophic Lateral Sclerosis Drug Market By Region, Through 2017Table 37 : Progressive Bulbar Palsy Drug Market By Region, Through 2017Table 38 : Hereditary Spastic Paraplegia Drug Market By Region, Through 2017Table 39 : Hereditary Neuropathy Drug Market By Region, Through 2017Table 40 : Multiple Sclerosis Drug Market By Region, Through 2017Table 41 : Progressive Weakness Syndrome Drug Market By Technology, Through 2017Table 42 : Progressive Weakness Market By Technology, 2011Table 43 : Multiple Sclerosis Drug Market By Technology, Through 2017Table 44 : Multiple Sclerosis Drug Market Distribution By Technology, 2011Table 45 : Leading Manufacturers And Suppliers Of Drugs And Therapies For Amyotrophic LateralSclerosisTable 46 : Market Shares Of Manufacturers And Distributors Amyotrophic Lateral Sclerosis Drugs,2011Table 47 : Leading Manufacturers And Suppliers Of Progressive Bulbar Palsy Drugs AndTherapiesTable 48 : Market Shares Of Manufacturers And Distributors Of Progressive Bulbar Palsy Drugs,2011Table 49 : Leading Manufacturers And Suppliers Of Hereditary Spastic Paraplegia Drugs AndTherapiesTable 50 : Market Shares Of Manufacturers And Distributors Of Hereditary Spastic ParaplegiaDrugs, 2011Table 51 : Leading Manufacturers And Suppliers Of Hereditary Neuropathy Drugs And Therapies
    • Table 52 : Market Shares Of Manufacturers And Distributors Of Hereditary Neuropathies Drugs,2011Table 53 : Leading Manufacturers And Suppliers Multiple Sclerosis Drugs And TherapiesTable 54 : Market Shares Of Manufacturers And Distributors Of Multiple Sclerosis Drugs, 2011Table 55 : Total Number Of Patents By Year, 2010-March 2012Table 56 : Patents By Disease Category, 2010-March 2012Table 57 : Patents For Progressive Ataxia Syndromes By Disease Type, 2010-2012Table 58 : Patents For Progressive Weakness And Effect The On Brain And Spinal CordSyndromes By Disease Type, 2010-2012Table 59 : U.S. Patents By Country For Progressive Ataxia Syndromes, 2010-2012Table 60 : Patent Shares By Country For Progressive Ataxia Syndromes, 2010-2012Table 61 : U.S. Patents By Country For Progressive Weakness And Effect On The Brain AndSpinal Cord Syndromes, 2010-2012Table 62 : Patent Shares By Country For Progressive Weakness And Effect On The Brain AndSpinal Cord Syndromes, 2010-2012Table 63 : U.S. Patents For Progressive Ataxia Syndromes By Company, 2010-2012Table 64 : U.S. Patents For Progressive Weakness And Effect On The Brain And Spinal CordSyndromes By Company, 2010-2012Table 65 : Patents For Progressive Ataxia Syndromes By Assignee, 2010-2012Table 66 : Patents For Progressive Weakness And Effect On The Brain And Spinal CordSyndromes By Assignee, 2010-2012List Of FiguresSummary Figure : Global Market For Progressive Ataxia And Weakness Disorders, 2010-2017Figure 1 : Global Revenues Of Drug Product For The Treatment Of NeurodegenerativeDysfunctions, 2010-2017Figure 2 : Market Share Of Drug Used For The Treatment Of Neurodegenerative Disorders ByDysfunction, 2011Figure 3 : Global Sales Of Drug Product For The Treatment Of Progressive Ataxia And WeaknessDisorders, 2010-2017Figure 4 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia AndWeakness Disorders, 2011Figure 5 : Market For Drug Products For The Treatment Of Progressive Ataxia And WeaknessDisorders By Region, 2010-2017Figure 6 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia AndWeakness Disorders By Region, 2011Figure 7 : Global Sales Of Drug Products For The Treatment Of Progressive Ataxia AndWeakness Disorders By Technology, 2010-2017Figure 8 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia AndWeakness Disorders By Technology, 2011Figure 9 : Sales Of Drug Products For The Treatment Of Progressive Ataxia By Disease Type,2010-2017Figure 10 : Progressive Ataxia Drug Market By Disease Type, 2011
    • Figure 11 : Progressive Ataxia Drug Market By Region, 2010-2017Figure 12 : Progressive Ataxia Drug Market By Region, 2011Figure 13 : Friedreich’s Ataxia Drug Market By Region, 2010-2017Figure 14 : Gertsmann-Straussler-Scheinker Disease Drug Market By Region, 2010-2017Figure 15 : Machado-Joseph Disease Drug Market By Region, 2010-2017Figure 16 : Progressive Ataxia Drug Market By Technology, 2010-2017Figure 17 : Progressive Ataxia Drugs Share By Technology, 2011Figure 18 : Market Shares Of Manufacturers And Distributors Of Friedreich’s Ataxia Drugs, 2011Figure 19 : Market Shares Of Manufacturers And Distributors Of Gertsmann-Straussler-ScheinkerDisease Drugs, 2011Figure 20 : Market Shares Of Manufacturers And Distributors Of Machado-Joseph Disease Drugs,2011Figure 21 : Progressive Weakness Syndrome Drug Market By Disease Type, 2010-2017Figure 22 : Progressive Weakness Drug Market By Disease Type, 2011Figure 23 : Progressive Weakness Syndrome Drug Market By Region, 2010-2017Figure 24 : Progressive Weakness Drug Market By Region, 2011Figure 25 : Amyotrophic Lateral Sclerosis Drug Market By Region, 2010-2017Figure 26 : Progressive Bulbar Palsy Drug Market By Region, 2010-2017Figure 27 : Hereditary Spastic Paraplegia Drug Market By Region, 2010-2017Figure 28 : Hereditary Neuropathy Drug Market By Region, 2010-2017Figure 29 : Multiple Sclerosis Drug Market By Region, 2010-2017Figure 30 : Progressive Weakness Syndrome Drug Market By Technology, 2010-2017Figure 31 : Progressive Weakness Market By Technology, 2011Figure 32 : Multiple Sclerosis Drug Market By Technology, 2010-2017Figure 33 : Multiple Sclerosis Drug Market Distribution By Technology, 2011Figure 34 : Market Shares Of Manufacturers And Distributors Of Amyotrophic Lateral SclerosisDrugs, 2011Figure 35 : Market Shares Of Manufacturers And Distributors Of Progressive Bulbar Palsy Drugs,2011Figure 36 : Market Shares Of Manufacturers And Distributors Of Hereditary Spastic ParaplegiaDrugs, 2011Figure 37 : Market Shares Of Manufacturers And Distributors Of Hereditary Neuropathy Drugs,2011Figure 38 : Market Shares Of Manufacturers And Distributors Of Multiple Sclerosis, Drugs 2011Figure 39 : Number Of Patents By Year, 2010–March 2012Figure 40 : Patents By Disease Category, 2010–March 2012Figure 41 : Patents For Progressive Ataxia Syndromes By Disease Type, 2010–2012Figure 42 : Patents For Progressive Weakness And Effect On Brain And Spinal Cord SyndromesBy Disease Type, 2010–2012Contact: sales@reportsandreports.com for more information.